Literature DB >> 7528470

Renal medullary carcinoma. The seventh sickle cell nephropathy.

C J Davis1, F K Mostofi, I A Sesterhenn.   

Abstract

Over the last 22 years, we have encountered 34 examples of a highly aggressive neoplasm with a microscopic morphology that is highly predictive of finding sickled erythrocytes in the tissue. With the exception of one patient, all are believed to have had sickle cell trait or, in one case, hemoglobin SC disease. These 33 patients are the subject of this report and, where their race was known, they were all blacks between the ages of 11 and 39 years. Between the ages of 11 and 24 years, males predominated by 3 to 1. Beyond age 24, however, the tumors occurred equally in men and women. The dominant tumor mass was in the medulla and ranged from 4 to 12 cm in diameter. Mean size was 7 cm; median, 6 cm. Peripheral satellites in the renal cortex and pelvic soft tissues, as well as venous and lymphatic invasion, were usually present. The lesions exhibited a reticular, yolk sac-like, or adenoid cystic appearance, often with poorly differentiated areas in a highly desmoplastic stroma admixed with neutrophils and usually marginated by lymphocytes. The tumors had usually metastasized when first discovered, and none was confined to the kidney at the time of nephrectomy. The mean duration of life after surgery was 15 weeks. These tumors probably arise in the calyceal epithelium in or near the renal papillae, the same site that produces the more familiar picture of unilateral hematuria in patients with sickle cell trait. We have concluded that renal medullary carcinoma represents another example of renal disease associated with sickle cell disorders. The other six are unilateral hematuria, papillary necrosis, nephrotic syndrome, renal infarction, inability to concentrate urine, and pyelonephritis.

Entities:  

Mesh:

Year:  1995        PMID: 7528470     DOI: 10.1097/00000478-199501000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  76 in total

1.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.

Authors:  Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg
Journal:  Am J Hematol       Date:  2012-02-03       Impact factor: 10.047

3.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 4.  Physiological responses of sickle cell trait carriers during exercise.

Authors:  Philippe Connes; Harvey Reid; Marie-Dominique Hardy-Dessources; Errol Morrison; Olivier Hue
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

5.  Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Mary Kleyn; Kevin J Dombkowski
Journal:  Blood Adv       Date:  2019-05-28

6.  High prevalence of sickle cell trait in African Americans with ESRD.

Authors:  Vimal K Derebail; Patrick H Nachman; Nigel S Key; Heather Ansede; Ronald J Falk; Abhijit V Kshirsagar
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

7.  Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Chisato Ohe; Steven C Smith; Deepika Sirohi; Mukul Divatia; Mariza de Peralta-Venturina; Gladell P Paner; Abbas Agaimy; Mitual B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Maurizio Colecchia; Eva Compérat; Isabela Werneck da Cunha; Jonathan I Epstein; Anthony J Gill; Ondřej Hes; Michelle S Hirsch; Wolfram Jochum; Lakshmi P Kunju; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Gabriella Nesi; Adeboye O Osunkoya; Maria M Picken; Priya Rao; Victor E Reuter; Paulo Guilherme de Oliveira Salles; Luciana Schultz; Satish K Tickoo; Scott A Tomlins; Kiril Trpkov; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

8.  Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil.

Authors:  Marina Cavalcanti Maroja Silvino; Camila Motta Venchiarutti Moniz; Gustavo Henrique Munhoz Piotto; Sheila Siqueira; Ariel Galapo Kann; Carlos Dzik
Journal:  Rare Tumors       Date:  2013-08-20

9.  Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition.

Authors:  Yamila Goenaga-Vázquez; Gloria Colón; Nilka Barrios; María Correa
Journal:  CEN Case Rep       Date:  2018-02-02

10.  Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Authors:  Pavlos Msaouel; Andrew L Hong; Elizabeth A Mullen; Michael B Atkins; Cheryl Lyn Walker; Chung-Han Lee; Marcus A Carden; Giannicola Genovese; W Marston Linehan; Priya Rao; Maria J Merino; Howard Grodman; Jeffrey S Dome; Conrad V Fernandez; James I Geller; Andrea B Apolo; Najat C Daw; H Courtney Hodges; Marva Moxey-Mims; Darmood Wei; Donald P Bottaro; Michael Staehler; Jose A Karam; W Kimryn Rathmell; Nizar M Tannir
Journal:  Clin Genitourin Cancer       Date:  2018-09-12       Impact factor: 2.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.